Uveal melanoma remains a significant challenge, with genetic alterations playing a crucial role in treatment decisions. In this episode, Prof. Jens Folke Kiilgaard (Denmark) and Dr. Emine Kilic (The Netherlands) join Prof. Antonia Joussen (Germany) to explore why metastases persist despite primary tumor treatment, the limitations of checkpoint inhibitors, and the latest on Tebentafusp and Darovasertib. We also discuss the role of adjuvant and neoadjuvant therapies and emerging T-cell therapies. Join us for an insightful discussion on the future of uveal melanoma treatment.
Members can continue the conversation in the EURETINA Forum.
Browse all podcast episodes here.
Listen on your preferred podcast player:
